Current therapy and drug pipeline for the treatment of patients with acromegaly

Advances in Therapy

Volumn 26, Issue 4, 2009, Pages 383-403

  Kumar, Sampath Satish ^a   Ayuk, John ^b   Murray, Robert D ^a  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Acromegaly; Dopaminergic agonist; Growth hormone; Growth hormone receptor antagonist; Insulin like growth factor I; Somatostatin

Indexed keywords

ALT 1103; ANGIOPEPTIN; ATL 1103; BIM 23190; BIM 23197; BIM 23244; BIM 23268; BIM 23454; BIM 23627; BIM 23745; BIM 23926; BIM 23A760; BIM 23A779; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPASTATIN; GLYCOSYLATED GROWTH HORMONE RECEPTOR BLOCKING AGENT; GROWTH HORMONE; HORMONE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; N 5 (AMINOSULFONYL) 2 METHYLPHENYL 5 BROMO 2 FURAMIDE; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PLACEBO; QUINAGOLIDE; SOMATOMEDIN C RECEPTOR; SOMATOSTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM;

ACROMEGALY; BINDING AFFINITY; BODY WEIGHT; CEREBROVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DRUG BINDING; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG IMPLANT; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; GAMMA KNIFE RADIOSURGERY; GROWTH HORMONE RELEASE; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; IC 50; LOW DRUG DOSE; MICROADENOMA; NONHUMAN; PARKINSON DISEASE; RADIATION DOSE; REMISSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; VALVULAR HEART DISEASE;

ACROMEGALY; ADENOMA; COMBINED MODALITY THERAPY; DOPAMINE; DOPAMINE AGONISTS; DRUG DISCOVERY; DRUG EVALUATION; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; PITUITARY NEOPLASMS; RADIOTHERAPY; RECEPTORS, DOPAMINE D2; RECEPTORS, SOMATOTROPIN; SOMATOSTATIN; TREATMENT OUTCOME;

EID: 73449114243     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0029-9     Document Type: Review

References (93)

1. L. Alexander D. Appleton R. Hall W.M. Ross R. Wilkinson 1980 Epidemiology of acromegaly in the Newcastle region Clin Endocrinol (Oxf). 12 71 79 10.1111/j.1365-2265.1980.tb03135.x 1:STN:280:DyaL3c3gtVektw%3D%3D
2. I.M. Holdaway C. Rajasoorya 1999 Epidemiology of acromegaly Pituitary 2 29 41 11081170 10.1023/A:1009965803750 1:STN:280:DC%2BD3M%2FksFKjtA%3D%3D
3. S. Melmed 2006 Medical progress: acromegaly N Engl J Med. 355 2558 2573 17167139 10.1056/NEJMra062453 1:CAS:528:DC%2BD28XhtlWqsbzK (Pubitemid 44917504)
4. A.S. Bates W. Van't Hoff J.M. Jones R.N. Clayton 1993 An audit of outcome of treatment in acromegaly Q J Med. 86 293 299 8327647 1:STN:280: DyaK3szhslyhug%3D%3D
5. S.M. Orme R.J. McNally R.A. Cartwright P.E. Belchetz 1998 Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group J Clin Endocrinol Metab. 83 2730 2734 9709939 10.1210/jc.83.8.2730 1:CAS:528:DyaK1cXltlWms7k%3D (Pubitemid 28493768)
6. A. Colao D. Ferone P. Marzullo G. Lombardi 2004 Systemic complications of acromegaly: epidemiology, pathogenesis, and management Endocr Rev. 25 102 152 14769829 10.1210/er.2002-0022 1:CAS:528:DC%2BD2cXhvFOmt7w%3D (Pubitemid 38269977)
7. I.M. Holdaway R.C. Rajasoorya G.D. Gamble 2004 Factors influencing mortality in acromegaly J Clin Endocrinol Metab. 89 667 674 14764779 10.1210/jc.2003-031199 1:CAS:528:DC%2BD2cXhsFOjsLY%3D (Pubitemid 38269875)
8. J. Ayuk R.N. Clayton G. Holder M.C. Sheppard P.M. Stewart A.S. Bates 2004 Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly J Clin Endocrinol Metab. 89 1613 1617 15070920 10.1210/jc.2003-031584 1:CAS:528:DC%2BD2cXjt1elsLo%3D (Pubitemid 38507910)
9. B. Swearingen F.G. Barker 2nd L. Katznelson 1998 Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly J Clin Endocrinol Metab. 83 3419 3426 9768641 10.1210/jc.83.10.3419 1:CAS:528:DyaK1cXmsFKlsrk%3D (Pubitemid 28500866)
10. N.J. Gittoes M.C. Sheppard A.P. Johnson P.M. Stewart 1999 Outcome of surgery for acromegaly-the experience of a dedicated pituitary surgeon Q J Med. 92 741 745 1:STN:280:DC%2BD3c7htlSqtQ%3D%3D
11. J. Kreutzer M.L. Vance M.B. Lopes E.R. Laws Jr. 2001 Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria J Clin Endocrinol Metab. 86 4072 4077 11549628 10.1210/jc.86.9.4072 1:CAS:528:DC%2BD3MXmvFCkt7w%3D (Pubitemid 32848515)
12. N.R. Biermasz H. van Dulken F. Roelfsema 2000 Tenyear follow-up results of transsphenoidal microsurgery in acromegaly J Clin Endocrinol Metab. 85 4596 4602 11134114 10.1210/jc.85.12.4596 1:CAS:528:DC%2BD3MXis1CltQ%3D%3D (Pubitemid 32157639)
13. C.M. Feek J. McLellard J. Seth 1984 How effective is external pituitary irradiation for growth hormonesecreting pituitary tumours? Clin Endocrinol (Oxf). 20 401 408 10.1111/j.1365-2265.1984.tb03435.x 1:STN:280: DyaL2c7otFWjuw%3D%3D
14. A.F. Macleod D.G. Clarke H. Pambakian C. Lowy P.H. Sonksen C.D. Collins 1989 Treatment of acromegaly by external irradiation Clin Endocrinol (Oxf). 30 303 314 10.1111/j.1365-2265.1989.tb02239.x 1:STN:280:DyaK3c%2FnsFCgsg%3D%3D
15. M.D. Littley S.M. Shalet C.G. Beardwell E.L. Robinson M.L. Sutton 1989 Radiation-induced hypopituitarism is dose-dependent. 31 363 373 1:STN:280:DyaK3c7ltVKgtw%3D%3D
16. M. Brada L. Burchell S. Ashley D. Traish 1999 The incidence of cerebrovascular accidents in patients with pituitary adenoma Int J Radiat Oncol Biol Phys. 45 693 698 10524424 1:STN:280:DyaK1Mvlt1Smtw%3D%3D
17. J.C. Flickinger P.B. Nelson F.H. Taylor A. Robinson 1989 Incidence of cerebral infarction after radiotherapy for pituitary adenoma Cancer. 63 2404 2408 2720586 10.1002/1097-0142(19890615)63:12<2404::AID-CNCR2820631205>3. 0.CO;2-3 1:STN:280:DyaL1M3kvVyguw%3D%3D (Pubitemid 19152744)
18. J.W. Tomlinson N. Holden R.K. Hills 2001 West Midlands Prospective Hypopituitary Study Group. Association between premature mortality and hypopituitarism Lancet. 357 425 431 11273062 10.1016/S0140-6736(00)04006-X 1:STN:280:DC%2BD3M7nt12itw%3D%3D (Pubitemid 32156141)
19. J.A. Wass 2003 Radiotherapy in acromegaly: a protagonist's viewpoint Clin Endocrinol (Oxf). 58 128 131 10.1046/j.1365-2265.2003.01706.x 1:STN:280:DC%2BD3s%2FntFWmtg%3D%3D (Pubitemid 36194263)
20. A.L. Barkan I. Halasz K.J. Dornfeld 1997 Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly J Clin Endocrinol Metab. 82 3187 3191 9329336 10.1210/jc.82.10.3187 1:CAS:528:DyaK2sXmslOiu70%3D (Pubitemid 27419054)
21. N.C. Thalassinos S. Tsagarakis G. Ioannides I. Tzavara C. Papavasiliou 1998 Megavoltage pituitary irradiation lowers but seldom leads to safe GH levels in acromegaly: a long-term follow-up study Eur J Endocrinol. 138 160 163 9506859 10.1530/eje.0.1380160 1:CAS:528:DyaK1cXhs1agtL8%3D (Pubitemid 28131092)
22. N.R. Biermasz H.V. Dulken F. Roelfsema 2000 Postoperative radiotherapy in acromegaly is effective in reducing GH concentration to safe levels Clin Endocrinol (Oxf). 53 321 327 10.1046/j.1365-2265.2000.01095.x 1:CAS:528:DC%2BD3cXnt1Kls70%3D
23. G. Barrande M. Pittino-Lungo J. Coste 2000 Hormonal and metabolic effects of radiotherapy in acromegaly: long-term results in 128 patients followed in a single center J Clin Endocrinol Metab. 85 3779 3785 11061538 10.1210/jc.85.10.3779 1:CAS:528:DC%2BD3cXnsFOgur0%3D
24. P.J. Jenkins P. Bates M.N. Carson P.M. Stewart J.A. Wass 2006 Conventional pituitary irradiation is effective in lowering serum growth hormone and insulinlike growth factor-I in patients with acromegaly J Clin Endocrinol Metab. 91 1239 1245 16403824 10.1210/jc.2005-1616 1:CAS:528:DC%2BD28XjvFOks7o%3D
25. A. Jadresic M. Poblete 1967 Stereotaxic pituitary implantation of yttrium-90 and iridium-192 for acromegaly J Clin Endocrinol Metab. 27 1503 1507 4862202 1:STN:280:DyaF1c%2Fks1SmsQ%3D%3D
26. A.D. Wright M. Hartog H. Palter 1970 The use of yttrium 90 implantation in the treatment of acromegaly Proc R Soc Med. 63 221 223 5445551 1:STN:280:DyaE3c7osl2ntA%3D%3D
27. F. Castinetti D. Taieb J.M. Kuhn 2005 Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion J Clin Endocrinol Metab. 90 4483 4488 15899958 10.1210/jc.2005-0311 1:CAS:528:DC%2BD2MXnvVWltL0%3D (Pubitemid 41159330)
28. E.O. Vik-Mo M. Oksnes P.H. Pedersen 2007 Gamma knife stereotactic radiosurgery for acromegaly Eur J Endocrinol. 157 255 263 17766706 10.1530/EJE-07-0189 1:CAS:528:DC%2BD2sXhtFantr7J (Pubitemid 47603528)
29. J. Jezkova J. Marek V. Hana 2006 Gamma knife radiosurgery for acromegaly - long-term experience Clin Endocrinol (Oxf). 64 588 595 10.1111/j.1365-2265. 2006.02513.x
30. A. Saveanu E. Lavaque G. Gunz 2002 Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells J Clin Endocrinol Metab. 87 5545 5552 12466351 10.1210/jc.2002-020934 1:CAS:528:DC%2BD38XpslWntLc%3D (Pubitemid 36034358)
31. M.O. Thorner A. Chait M. Aitkin 1975 Bromocriptine treatment of acromegaly Br Med J. 1 299 303 1111790 10.1136/bmj.1.5953.299 1:STN:280:DyaE2M%2FptFGhug%3D%3D
32. S. Melmed K. Ho A. Klibanski S. Reichlin M. Thorner 1995 Clinical review 75: recent advances in pathogenesis, diagnosis, and management of acromegaly J Clin Endocrinol Metab. 80 3395 3402 8530571 10.1210/jc.80.12.3395 1:CAS:528:DyaK2MXpvFSjtrs%3D
33. R. Abs J. Verhelst D. Maiter 1998 Cabergoline in the treatment of acromegaly: a study in 64 patients J Clin Endocrinol Metab. 83 374 378 9467544 10.1210/jc.83.2.374 1:CAS:528:DyaK1cXhtVSnt7Y%3D (Pubitemid 28496509)
34. A. Colao D. Ferone P. Marzullo 1997 Effect of different dopaminergic agents in the treatment of acromegaly J Clin Endocrinol Metab. 82 518 523 9024247 10.1210/jc.82.2.518 1:CAS:528:DyaK2sXhtVWktLw%3D (Pubitemid 27068622)
35. R. Zanettini A. Antonini G. Gatto R. Gentile S. Tesei G. Pezzoli 2007 Valvular heart disease and the use of dopamine agonists for Parkinson's disease N Engl J Med. 356 39 46 17202454 10.1056/NEJMoa054830 1:CAS:528: DC%2BD2sXitlCgsQ%3D%3D
36. R. Schade F. Andersohn S. Suissa W. Haverkamp E. Garbe 2007 Dopamine agonists and the risk of cardiac-valve regurgitation N Engl J Med. 356 29 38 17202453 10.1056/NEJMoa062222 1:CAS:528:DC%2BD2sXitlCgsg%3D%3D
37. J.J. Kopchick C. Parkinson E.C. Stevens P.J. Trainer 2002 Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly Endocr Rev. 23 623 646 12372843 10.1210/er.2001-0022 1:CAS:528:DC%2BD38XosVejsbk%3D (Pubitemid 35191626)
38. J.J. Kopchick 2003 Discovery and mechanism of action of pegvisomant Eur J Endocrinol. 148 suppl.2 21 25 10.1530/eje.0.148S021
39. P.J. Trainer W.M. Drake L. Katznelson 2000 Treatment of acromegaly with the growth hormonereceptor antagonist pegvisomant N Engl J Med. 342 1171 1177 10770982 10.1056/NEJM200004203421604 1:CAS:528:DC%2BD3cXjtVOkur4%3D (Pubitemid 30211048)
40. A.J. Van der Lely R.K. Hutson P.J. Trainer 2001 Longterm treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist Lancet. 358 1754 1759 11734231 10.1016/S0140-6736(01)06844-1 (Pubitemid 33152999)
41. I. Schreiber M. Buchfelder M. Droste 2007 Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study Eur J Endocrinol. 156 75 82 17218728 10.1530/eje.1.02312 1:CAS:528:DC%2BD2sXntlyqtbk%3D (Pubitemid 46553905)
42. T. Reisine G.I. Bell 1995 Molecular biology of somatostatin receptors Endocr Rev. 16 427 442 8521788 1:CAS:528:DyaK2MXotl2rt7s%3D
43. A. Schonbrunn 1999 Somatostatin receptors present knowledge and future directions Ann Oncol. 10 suppl.2 S17 S21 10399028 10.1023/A:1027392228418
44. S.E. Christensen J. Nerup A.P. Hansen K. Lundbaek 1976 Effects of somatostatin on basal levels of plasma growth hormone and insulin in acromegalics: dose-response studies and attempted total growth hormone suppression J Clin Endocrinol Metab. 42 839 845 773950 1:CAS:528: DyaE28XksVWnsr0%3D
45. S.S. Yen T.M. Siler G.W. DeVane 1974 Effect of somatostatin in patients with acromegaly: suppression of growth hormone, prolactin, insulin and glucose levels N Engl J Med. 290 935 938 4593614 1:STN:280:DyaE2c7it12msQ%3D%3D
46. M.C. Zatelli D. Piccin F. Tagliati 2005 Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro J Mol Endocrinol. 35 333 341 16216913 10.1677/jme.1.01876 1:CAS:528:DC%2BD2MXhtFyhsLfJ (Pubitemid 41556180)
47. A. Saveanu G. Gunz H. Dufour 2001 BIM-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas J Clin Endocrinol Metab. 86 140 145 11231991 10.1210/jc.86.1.140 1:CAS:528: DC%2BD3MXhtVGnsrc%3D (Pubitemid 32109787)
48. I. Shimon J.E. Taylor J.Z. Dong 1997 Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation J Clin Invest. 99 789 798 9045884 10.1172/JCI119225 1:CAS:528:DyaK2sXhtlWgu78%3D
49. G. Tulipano C. Bonfanti G. Milani 2001 Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro Neuroendocrinology. 73 344 351 11399907 10.1159/000054651 1:CAS:528:DC%2BD3MXksFKgtL4%3D (Pubitemid 32588858)
50. P. Jaquet G. Gunz A. Saveanu 2005 Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy Eur J Endocrinol. 153 135 141 15994755 10.1530/eje.1.01950 1:CAS:528:DC%2BD2MXntValu74%3D (Pubitemid 41030524)
51. S.G. Ren S. Kim J. Taylor 2003 Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand J Clin Endocrinol Metab. 88 5414 5421 14602782 10.1210/jc.2003-030302 1:CAS:528:DC%2BD3sXptVyntrk%3D (Pubitemid 37452747)
52. C. Bruns I. Lewis U. Briner G. Meno-Tetang G. Weckbecker 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile Eur J Endocrinol. 146 707 716 11980628 10.1530/eje.0.1460707 1:CAS:528: DC%2BD38XktFGitr4%3D
53. A. Fusco G. Gunz P. Jaquet 2008 Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas Eur J Endocrinol. 158 595 603 18426817 10.1530/EJE-07-0806 1:CAS:528:DC%2BD1cXmtlanurw%3D (Pubitemid 351639596)
54. P.U. Freda L. Katznelson A.J. van der Lely C.M. Reyes S. Zhao D. Rabinowitz 2005 Long-acting somatostatin analog therapy of acromegaly: a meta-analysis J Clin Endocrinol Metab. 90 4465 4473 15886238 10.1210/jc.2005-0260 1:CAS:528:DC%2BD2MXnvVWltL8%3D (Pubitemid 41159328)
55. R.D. Murray S. Melmed 2008 A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly J Clin Endocrinol Metab. 93 2957 2968 18477663 10.1210/jc.2008-0027 1:CAS:528:DC%2BD1cXpvVOmurY%3D
56. J.C. Reubi A.M. Landolt 1989 The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status J Clin Endocrinol Metab. 68 844 850 2537844 1:STN:280:DyaL1M7lsFOjuw%3D%3D
57. A. Saveanu P. Jaquet T. Brue A. Barlier 2008 Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas Mol Cell Endocrinol. 286 206 213 18241980 10.1016/j.mce.2007.12.008 1:CAS:528: DC%2BD1cXmtVSmtL4%3D
58. M.C. Zatelli D. Piccin F. Tagliati 2003 Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion J Clin Endocrinol Metab. 88 2797 2802 12788890 10.1210/jc.2002-021825 1:CAS:528:DC%2BD3sXkslCrsLY%3D
59. D.C. Danila J.N. Haidar X. Zhang L. Katznelson M.D. Culler A. Klibanski 2001 Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors J Clin Endocrinol Metab. 86 2976 2981 11443154 10.1210/jc.86.7.2976 1:CAS:528:DC%2BD3MXlt1Gjs7c%3D (Pubitemid 32673451)
60. L.J. Hofland S.W. Lamberts 2003 The pathophysiological consequences of somatostatin receptor internalization and resistance Endocr Rev. 24 28 47 12588807 10.1210/er.2000-0001 1:CAS:528:DC%2BD3sXhslOgsbw%3D (Pubitemid 36223278)
61. L.J. Hofland J. van der Hoek P.M. van Koetsveld 2004 The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone-and prolactin-secreting pituitary adenomas in vitro J Clin Endocrinol Metab. 89 1577 1585 15070915 10.1210/jc.2003-031344 1:CAS:528: DC%2BD2cXjt1els7c%3D (Pubitemid 38507905)
62. C. Matrone R. Pivonello A. Colao 2004 Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs Neuroendocrinology. 79 142 148 15103227 10.1159/000077272 1:CAS:528:DC%2BD2cXjsF2kurg%3D (Pubitemid 38581688)
63. P. Jaquet A. Saveanu G. Gunz 2000 Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes J Clin Endocrinol Metab. 85 781 792 10690891 10.1210/jc.85.2.781 1:CAS:528:DC%2BD3cXhtlygsrs%3D (Pubitemid 32273669)
64. G. Tulipano D. Soldi M. Bagnasco 2002 Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term highdose dexamethasone treatment Endocrinology. 143 1218 1224 11897676 10.1210/en.143.4.1218 1:CAS:528:DC%2BD38XisFGisrg%3D (Pubitemid 34274350)
65. I. Shimon X. Yan J.E. Taylor M.H. Weiss M.D. Culler S. Melmed 1997 Somatostatin receptor (SSTR) subtypeselective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors J Clin Invest. 100 2386 2392 9410919 10.1172/JCI119779 1:CAS:528:DyaK2sXnt1GgsbY%3D
66. M. Grant R.C. Patel U. Kumar 2004 The role of subtypespecific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors J Biol Chem. 279 38636 38643 15247250 10.1074/jbc.M406276200 1:CAS:528:DC%2BD2cXnt1Oqurk%3D (Pubitemid 39296019)
67. M. Pfeiffer T. Koch H. Schroder 2001 Homo- and heterodimerization of somatostatin receptor sub-types. Inactivation of sst(3) receptor function by heterodimerization with sst(2A) J Biol Chem. 276 14027 14036 11134004 1:CAS:528:DC%2BD3MXjt12rs7s%3D
68. M. Rocheville D.C. Lange U. Kumar R. Sasi R.C. Patel Y.C. Patel 2000 Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers J Biol Chem. 275 7862 7869 10713101 10.1074/jbc.275.11.7862 1:CAS:528:DC%2BD3cXitVyltr4%3D (Pubitemid 30159693)
69. N. Sharif L. Gendron J. Wowchuk 2007 Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2 Endocrinology. 148 2095 2105 17272399 10.1210/en.2006-1266 1:CAS:528:DC%2BD2sXkvFCgsrg%3D (Pubitemid 46997042)
70. G. Weckbecker U. Briner I. Lewis C. Bruns 2002 SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulinlike growth factor-I axis in rats, primates, and dogs Endocrinology. 143 4123 4130 12239124 10.1210/en.2002-220219 1:CAS:528:DC%2BD38Xnt1ygtL4%3D (Pubitemid 35244391)
71. M. Rocheville D.C. Lange U. Kumar S.C. Patel R.C. Patel Y.C. Patel 2000 Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity Science. 288 154 157 10753124 10.1126/science.288. 5463.154 1:CAS:528:DC%2BD3cXisVGku7o%3D (Pubitemid 30203051)
72. R. Cozzi R. Attanasio S. Lodrini G. Lasio 2004 Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status Clin Endocrinol (Oxf). 61 209 215 10.1111/j.1365-2265.2004.02082.x 1:CAS:528:DC%2BD2cXnslWltrc%3D (Pubitemid 39093116)
73. S.W. Lamberts M. Zweens L. Verschoor E. del Pozo 1986 A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs J Clin Endocrinol Metab. 63 16 19 2872225 1:STN:280:DyaL283isVChuw%3D%3D 10.1210/jcem-63-1-16
74. A. Baragli H. Alturaihi H.L. Watt A. Abdallah U. Kumar 2007 Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 co-immunoprecipitation and fluorescence resonance energy transfer analysis Cell Signal. 19 2304 2316 17706924 10.1016/j.cellsig.2007.07.007 1:CAS:528: DC%2BD2sXhtVWmtbrI (Pubitemid 47361686)
75. R.D. Murray K. Kim S.G. Ren 2004 The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion J Clin Endocrinol Metab. 89 3027 3032 15181094 10.1210/jc.2003-031319 1:CAS:528: DC%2BD2cXmtlKjsLY%3D (Pubitemid 38766404)
76. R.D. Murray K. Kim S.G. Ren M. Chelly Y. Umehara S. Melmed 2004 Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis J Clin Invest. 114 349 356 15286801 1:CAS:528:DC%2BD2cXmtlynsrg%3D
77. M. Fedele I. De Martino R. Pivonello 2007 SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/ prolactinsecreting pituitary adenomas Clin Cancer Res. 13 2738 2744 17473207 10.1158/1078-0432.CCR-06-2505 1:CAS:528:DC%2BD2sXkslOhurk%3D (Pubitemid 46788042)
78. A. Saveanu G. Gunz S. Guillen H. Dufour M.D. Culler P. Jaquet 2006 Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas Neuroendocrinology. 83 258 263 17047391 10.1159/000095536 1:CAS:528:DC%2BD28XhtV2hu7vE (Pubitemid 44578880)
79. S. Lesche D. Lehmann F. Nagel H.A. Schmid S. Schulz 2009 Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro J Clin Endocrinol Metab. 94 654 661 19001514 10.1210/jc.2008-1919 1:CAS:528:DC%2BD1MXhvFCqt7s%3D
80. P. Ma Y. Wang J. van der Hoek 2005 Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly Clin Pharmacol Ther. 78 69 80 16003295 10.1016/j.clpt.2005.04.003 1:CAS:528:DC%2BD2MXlvFKru7g%3D (Pubitemid 40956933)
81. J. van der Hoek W.W. de Herder R.A. Feelders 2004 A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients J Clin Endocrinol Metab. 89 638 645 14764775 10.1210/jc.2003-031052 1:CAS:528:DC%2BD2cXhsFOjsLo%3D (Pubitemid 38269871)
82. J. van der Hoek A.J. van der Lelij R.A. Feelders 2005 The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients Clin Endocrinol (Oxf). 63 176 184 10.1111/j.1365-2265.2005.02322.x 1:CAS:528:DC%2BD2MXpslGhsLc%3D (Pubitemid 41097986)
83. Farrall AJ, Glusman JE, Buchelt A, Goa B, Petersenn S. Pasireotide (SOM230) effectively reduces pituitary tumor volume in patients with active acromegaly: Results from a phase II trial. Presented at: 89th Annual Meeting of the American Endocrine Society; June 2-5, 2007; Toronto, Canada. Abstract OR53-54.
84. Schmid HA, Brueggen J, Guitard P. Effects of a longacting release formulation of pasireotide (SOM230) on hormone secretion in rats. Presented at: 89th Annual Meeting of the American Endocrine Society; June 2-5, 2007; Toronto, Canada. Abstract 3-337.
85. Petersenn S, Bollerslev J, Arafat AM, et al. Pasireotide LAR shows efficacy in patients with acromegaly: interim results from a randomised, multi-centre, phartmacokinetic/pharmacodynamic, phase I study. Presented at: 90th Annual Meeting of the American Endocrine Society; June 15-18, 2008; San Fransisco, CA. Abstract OR41-5.
86. H.A. Schmid 2008 Pasireotide (SOM230): Development, mechanism of action and potential applications Mol Cell Endocrinol. 286 69 74 17977644 10.1016/j.mce.2007.09.006 1:CAS:528:DC%2BD1cXmtVSmtbs%3D (Pubitemid 351680237)
87. L.A. Nolan H.A. Schmid A. Levy 2007 Octreotide and the novel multireceptor ligand somatostatin receptor agonist pasireotide (SOM230) block the adrenalectomy-induced increase in mitotic activ ity in male rat anterior pituitary Endocrinology. 148 2821 2827 17347306 10.1210/en.2006-1719 1:CAS:528:DC%2BD2sXmt1ajtLc%3D (Pubitemid 46984783)
88. M.C. Zatelli D. Piccin C. Vignali 2007 Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion Endocr Relat Cancer. 14 91 102 17395978 10.1677/ERC-06-0026 1:CAS:528: DC%2BD2sXhtlaksbnP (Pubitemid 47521725)
89. A. Gruszka S.G. Ren J. Dong M.D. Culler S. Melmed 2007 Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules Endocrinology. 148 6107 6114 17656461 10.1210/en.2007-0378 1:CAS:528:DC%2BD2sXhsVers7rI (Pubitemid 350146153)
90. T. Florio F. Barbieri R. Spaziante 2008 Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study Endocr Relat Cancer. 15 583 596 18509006 10.1677/ERC-07-0271 1:CAS:528:DC%2BD1cXosVGjsbg%3D (Pubitemid 351880845)
91. S. Parekh V. Srinivasan M. Horn 2008 Bioprocessing using novel cell culture systems Adv Appl Microbiol. 63 105 143 18395126 10.1016/S0065-2164(07) 00003-2 1:CAS:528:DC%2BD1cXpsVKru7o%3D
92. L. Rosengren V. Parrow J. Chmielewska A. Mode K. Fholenhag 2007 In vivo evaluation of a novel, orally bioavailable, small molecule growth hormone receptor antagonist Growth Horm IGF Res. 17 47 53 17161642 10.1016/j.ghir.2006. 10.006 1:CAS:528:DC%2BD2sXitl2iur4%3D (Pubitemid 46313079)
93. G. Tachas S. Lofthouse C.J. Wraight 2006 A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-I production and body weight gain in normal mice J Endocrinol. 189 147 154 16614389 10.1677/joe.1.06553 1:CAS:528:DC%2BD28Xkslaqtrs%3D (Pubitemid 43670709)